Startseite › Akute myeloische Leukämie › Minnesota › Minneapolis
Klinische Studien zu Akute myeloische Leukämie in Minneapolis, MN
20 Studien zu Akute myeloische Leukämie suchen Teilnehmer an Standorten in und um Minneapolis (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi entfernt
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Teilnehmer gesuchtPhase 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi entfernt
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Teilnehmer gesuchtPhase 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi entfernt
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Teilnehmer gesuchtPhase 1
- University of Minnesota/Masonic Cancer Center, Minneapolis
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Teilnehmer gesuchtPhase 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi entfernt
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Teilnehmer gesuchtPhase 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi entfernt
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Teilnehmer gesuchtPhase 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi entfernt
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Teilnehmer gesuchtPhase 3
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Teilnehmer gesuchtPhase 1/2
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Teilnehmer gesuchtPhase 3
- Masonic Cancer Center, Minneapolis
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Teilnehmer gesuchtPhase 3
- University of Minnesota, Minneapolis
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
Teilnehmer gesuchtPhase 1/2
- Masonic Cancer Center, Minneapolis
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Teilnehmer gesuchtPhase 1
- Masonic Cancer Center, Minneapolis
Allo HSCT Using RIC and PTCy for Hematological Diseases
Teilnehmer gesuchtPhase 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Teilnehmer gesuchtPhase 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
Teilnehmer gesuchtPhase 1/2
- Mark Juckett, MD, Minneapolis
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Teilnehmer gesuchtPhase 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Backtracking Leukemia-Typical Somatic Mutations in Cord Blood
Teilnehmer gesuchtBeobachtungsstudie
- University of Minnesota/Masonic Cancer Center, Minneapolis
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Teilnehmer gesuchtPhase 2
- University of Minnesota Masonic Cancer Center, Minneapolis
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Teilnehmer gesuchtPhase 1
- University of Minnesota, Minneapolis
Akute myeloische Leukämie-Studien in anderen Städten
- Houston, TX85 Studien
- New York City, NY51 Studien
- Boston, MA44 Studien
- Baldwin Park, CA40 Studien
- Seattle, WA40 Studien
- Columbus, OH35 Studien
- Philadelphia, PA34 Studien
- Durham, NC33 Studien
- Atlanta, GA30 Studien
- Tampa, FL29 Studien
- Chicago, IL26 Studien
- Portland, OR25 Studien
Weitere Studien in Minneapolis
- Brustkrebs27 Studien
- Nichtkleinzelliges Lungenkarzinom26 Studien
- Eierstockkrebs24 Studien
- Prostatakrebs23 Studien
- Krebs (alle Arten)22 Studien
- Herzinsuffizienz21 Studien
- Lungenkrebs20 Studien
- Kolorektales Karzinom19 Studien
- Endometriumkarzinom18 Studien
- Parkinson-Krankheit17 Studien
- Herz-Kreislauf-Erkrankungen15 Studien
- Koronare Herzkrankheit13 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 05.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.